UA-16322392-1
 



2954_v2
non_gmoPrint

Serrazimes
90 капсули

1621  МКД

Производот е на залиха

ИСБН: 037

Опис на продуктот

 

Serrazimes® е протеолитичка мешавина составена од ензими добиени од печурки, Aspergillus oryzae и Aspergillus melleus. Serrazimes® делува систематски на одржување на балансирана реакција на имунолошкиот систем преку помагање да се разложат протеинските имунолошки клеточни секрети, со што се овозможува нивно отстранување. На овој начин, Serrazimes® може да го подобри васкуларното и респираторното здравје, поддржувајќи ги природните процеси на организмот за исфрлање и опоравување.

  • 20.000 единици активитет
  • Системски протеолитички ензими
  • Васкуларна поддршка
  • Здрава имунолошка функција
Состав 1 капсула
Serrazimes® (20,000 Serratiopeptidase единици) 33 mg

Препорака за употреба: Како додаток во исхраната земете 1 капсула 1-2 пати дневно, помеѓу оброци. Производот се користи на празен стомак.

Други додатоци: трици, целулоза прав и целулоза (капсула).
Не е произведено со пченица, соја, млеко, јајца, риба, школки или јаткасти состојки. Произведено во GMP капацитет кој произведува други состојки кои ги содржат овие алергени.
Serrazimes® е заштитена трговска марка на National Enzyme Company.
Вегетеријански/Веган производ.

Предупредување: Само за возрасни. Консултирајте доктор доколку сте бремени или доилка, земате лекови (особено лекови за разредување на крвта) или имате некаква медицинска состојба.

Да се чува подалеку од дофат на деца! Пакетчето за свежина не е за јадење. Оставете го во шишенцето. Препорачаната дневна доза да не се надминува. Овој производ не е наменет за третман, превенција или лекување на специфична болест или состојба и не претставува замена за оброк. Чувајте го на ладно, суво место после отварање. Природни варијации на бојата може да се случат кај овој производ.

Потекло: САД, Производител: Now Foods, САД

 

 

Повеќе информации

Function
Serrapeptidase is a protease initially isolated from Serratia marcescens, a potentially pathogenic bacteria,found in the gut of the Japanese silkworm. Recognized as a pharmaceutical agent and sold under the names Danzen and Aniflazyme, Serrapeptidase has wide clinical use in Asia and Europe for the treatment of assorted inflammatory disorders (Rothschild, 1991). In recent years, recognition of the efficacy of this product has lead to growing interest in the US dietary supplement market. Despite international regulations, the product’s efficacy and availability over the internet has fueled its popularity in the US dietary supplement industry where it is used for anti-inflammatory support, cardiovascular support, respiratory support, and as an adjunct to antibiotic therapy. Recognizing the potential for a “Serrapeptidase-type” enzyme in the U.S. dietary supplement market, National Enzyme Company set fourth to develop a protease system that has the same in vitro activity as Serrapeptidase, but that is from a source organism(s) that has a long history of safe use in dietary supplements. Serrazimes™ is the product of this search.
Serrapeptidase has been used in Europe and Asia to treat heart disease, inflammatory diseases, and bacterial infections for over 25 years. The proteolytic activities of Serrapeptidase explain these applications. Serrazimes™ exhibits these same proteolytic activities in vitro, demonstrating that Serrazimes™ is an excellent alternative for Serrapeptidase in supplements intended to provide cardiovascular, antiinflammatory, respiratory, or immune support.
Since the 1960’s plant and microbial proteases have been studied for their role in the treatment of inflammation and inflammatory disorders. In both animal and human trials, proteolytic enzymes, from a variety of sources, have repeatedly been shown to significantly reduce inflammation resulting from sickness or injury. Early research on the anti-inflammatory actions of proteases pointed entirely to their antithrombic and fibrinolytic aspects to explain this phenomenon. However, studies by Parmely and others indicate that, in addition to degrading fibrin, microbial proteases may actually inactivate pro-inflammatory cytokines to prevent or attenuate inflammatory cascades.

Evidence suggests this may be accomplished through hydrolysis of tumor necrosis factor alpha (TNFα) and/or interferon gamma (IFNγ). Numerous human trials have shown Serrapeptidase to be highly effective for treating the inflammation resulting from carpal tunnel syndrome, surgery/injury, and breast engorgement. Serrazimes™ shows in vitro activity similar to Serrapeptidase, but uses a protease system from Aspergillus melleus and Aspergillus oryzae. Like Serrapeptidase, protease from Aspergillus melleus has been shown both in vitro and in vivo to significantly inhibit inflammatory responses. However, in a head to head in vivo trial between protease from Aspergillus melleus and Serrapeptidase, protease from Aspergillus melleus not only showed better anti-inflammatory results than Serrapeptidase, but it also showed fewer side effects. For these reasons, it is clear that Serrazimes™ is not only an adequate substitution for Serrapeptidase in anti-inflammatory products, it may even be the better choice.
Cardiovascular Support
Proteases may play an important role in minimizing the effects of heart disease and in the prevention of heart attacks. In heart disease, blood flow to the heart is blocked, either by a blood clot or by aggregated arterial plaques (atherosclerosis). More and more, the medical community is coming to recognize that cardiovascular diseases like atherosclerosis and heart attack are actually symptoms of inflammatory venous disease. A clinical study of 40 patients suffering from inflammatory venous disease tested the efficacy of Serrapeptidase in the treatment of thrombophlebitis. Serrapeptidase showed positive results in the treatment of this disorder for a majority of patients. However, this same study also tested the effectiveness of Aspergillus melleus protease for this condition. Aspergillus protease was shown to be superior to Serrapeptidase in both effectiveness and tolerability.

Respiratory Support
Because of their anti-inflammatory and mucolytic properties, proteases have been studied for the treatment of chronic, non-viral, respiratory disorders including sinusitus, otitis, and asthma since the 1960’s. Studies on Serrapeptidase and other proteases show that treatment with proteases can result in marked improvement in mucous viscosity and the inflammation of mucous membranes. In a head to head study, protease from Aspergillus melleus and Serrapeptidase both showed the ability to improve the viscoelasticity and clearance of sputum. However, caution should be used when administering Serrapeptidase to patients with symptoms of respiratory infections. While other proteases historically used as dietary supplements have actually been shown effective in treating viral infections, in vitro studies, animal studies, and adverse event reports indicate that Serrapeptidase may have the potential to increase both the incidence and severity of certain viral infections, including influenza and pneumonia. For this reason, persons with compromised immune systems, such as HIV infected patients, chemotherapy patients, or organ transplant patients, should be cautious in the use of Serrapeptidase. There is no evidence to suggest that Serrazimes™ elicits the same adverse reactions.
Antibacterial Support
Serrapeptidase has been shown to augment the activity of numerous antibiotic agents, including ampicillin, ciclacillin, cephalexin, minocylcine, and cefotiam. A study of the interaction between proteases from Aspergillus melleus and erythromycin shows that this protease has similar capabilities. In one such study pharmacologic synergism between this protease and erythromycin allowed the antibiotic to better penetrate and sterilize bronchial mucosa.

Side Effects, Contraindications, and Drug Interactions
Systemically used proteases are known to have antithrombic properties. Persons who suffer from clotting disorders or who are on antithrombic medications, such as warfarin, coumadin, or aspirin therapy may experience increased clotting times when using systemic proteases. Such persons should consult a physician prior to taking systemic doses of any protease, including Serrazimes™. Due to its effects on vascular permeability, the absorption and tissue distribution of antibiotics may be increased when administered concomitantly with Serrazimes™. Persons on antibiotics should consult their physicians prior to taking Serrazimes™.